Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its registration submission to the Food and
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity, and pharynx) cancer each year worldwide, with
Vigilant Biosciences has received the European Conformity (CE) mark for its OncAlert Oral Cancer RAPID Test, enabling the company to market the product in the